Florida Blue — Blue Cross and Blue Shield of Florida, the state's largest health insurer with approximately 6 million members — covers GLP-1 receptor agonists only for type 2 diabetes on commercial plans. Wegovy, Zepbound, and Saxenda prescribed for weight management are a categorical benefit exclusion. Florida Blue does not cover or approve prior authorization requests for off-label indications, including weight loss. The only exception path for obesity-indicated GLP-1s is through Medicare Part D plans, where Wegovy may be covered for cardiovascular risk reduction and MASH.
This guide maps which GLP-1 medications Florida Blue covers, details the prior authorization criteria administered through Prime Therapeutics, explains the weight-loss exclusion, and provides a plan-by-plan coverage summary. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.
Quick answer
| GLP-1 Drug | Florida Blue Commercial | Florida Blue Medicare (Part D) |
|---|---|---|
| Ozempic (semaglutide injection) | Covered — T2D with PA; preferred | Covered — T2D with PA |
| Mounjaro (tirzepatide injection) | Covered — T2D with PA; preferred | Covered — T2D with PA |
| Rybelsus (semaglutide tablets) | Covered — T2D with PA; preferred | Covered — T2D with PA |
| Trulicity (dulaglutide) | Covered — T2D with PA; preferred | Covered — T2D with PA |
| Wegovy (semaglutide 2.4 mg) | Excluded for weight loss (benefit exclusion) | Covered for CVD risk reduction and MASH with PA; weight loss excluded per CMS |
| Zepbound (tirzepatide) | Excluded (benefit exclusion) | Covered for OSA with PA; weight loss excluded per CMS |
| Saxenda (liraglutide 3 mg) | Excluded (benefit exclusion) | Excluded |
| Victoza (liraglutide) | Not covered on commercial | Covered — T2D with PA |
Key policy dates:
April 1, 2024: Florida Blue updated GLP-1 prior authorization criteria — providers must now submit clinical documentation of T2D diagnosis and metformin failure
January 2025: Florida Blue issued provider bulletin confirming GLP-1 coverage for FDA-approved T2D indications only; weight-loss PA submissions result in automatic denial
2026 (ongoing): Florida Blue commercial plans maintain T2D-only GLP-1 coverage; Medicare Part D plans expand Wegovy coverage for cardiovascular and MASH indications per CMS
Who this is for
Florida Blue commercial members (BlueChoice, BlueOptions, BlueSelect, BlueCare, myBlue, SimplyBlue, Truli for Health) and their prescribers
Florida Blue Medicare members with Part D prescription drug coverage
Benefit verification specialists and hub teams handling Florida Blue pharmacy claims
Market access teams at GLP-1 manufacturers tracking Florida Blue policy
Providers submitting GLP-1 PA requests through CoverMyMeds or Prime Therapeutics
Florida Blue plan structure
Florida Blue operates under GuideWell, a mutual insurance holding company. The key plan types that affect GLP-1 coverage:
BlueChoice: Preferred provider organization (PPO) commercial plans
BlueOptions: Health maintenance organization (HMO) commercial plans
BlueSelect: Narrow-network commercial plans
myBlue: Individual and family plans
SimplyBlue: Simplified plan design
Truli for Health: Small business plans
Florida Blue Medicare: Medicare Advantage and Part D plans
Each plan type uses a different formulary (Open Medication Guide, NetResults, or ValueScript Rx), but all share the same T2D-only GLP-1 coverage policy for commercial plans.
Type 2 diabetes GLP-1 coverage
Preferred GLP-1 drugs
Florida Blue identifies the following as preferred GLP-1 medications covered for type 2 diabetes:
Mounjaro (tirzepatide)
Ozempic (semaglutide injection)
Rybelsus (semaglutide tablets)
Trulicity (dulaglutide)
Victoza (liraglutide) — covered on Medicare plans only; not available on commercial formularies
These medications are placed on preferred tiers of the formulary but require prior authorization.
PA criteria for T2D
Florida Blue administers GLP-1 PA through Prime Therapeutics, its pharmacy benefit manager. The PA criteria for T2D GLP-1 coverage require:
Documented type 2 diabetes diagnosis: Clinical documentation confirming T2D, including:
HbA1c results
Fasting plasma glucose levels
Provider attestation of diabetes diagnosis
Metformin trial requirement: Documentation that the patient has tried and failed metformin, other metformin combination drugs, or insulin — this demonstrates medical necessity for GLP-1 approval
FDA-approved indication: The GLP-1 must be prescribed for an FDA-approved T2D indication only
No off-label use: Florida Blue does not cover or approve PA requests for off-label indications
From Florida Blue's GLP-1 Drug Class Overview Bulletin:
"Providers are required to provide clinical documentation of type 2 diabetes diagnosis when submitting a request for approval. Providers must submit documentation indicating the patient has tried and failed metformin, other metformin combination drugs, or insulin to demonstrate medical necessity for GLP-1 approval."
Formulary tier placement
Florida Blue's formularies (Open, NetResults, ValueScript Rx) tier GLP-1 T2D medications as follows:
| Drug | Tier | PA | Quantity Limits |
|---|---|---|---|
| Ozempic | Tier 2–3 | Yes | Per FDA max |
| Mounjaro | Tier 2–3 | Yes | Per FDA max |
| Rybelsus | Tier 2 | Yes | 1 tablet/day |
| Trulicity | Tier 2–3 | Yes | Per FDA max |
Tier placement varies by specific formulary and plan type. Higher tiers result in higher member cost-sharing.
Weight-loss GLP-1 exclusion
The exclusion policy
Florida Blue's policy on GLP-1 medications for weight loss is one of the most restrictive among major commercial payers:
Medications used for weight loss/management are excluded from coverage under Florida Blue's commercial health insurance plans
Requesting an authorization for Wegovy, Zepbound, Saxenda, or other medications for weight loss/management will result in denial
This is a benefit exclusion, not a formulary management decision — it cannot be appealed as a medical necessity determination
Patients will have to pay for these medications out of pocket
From Florida Blue's January 2025 provider bulletin:
"If you believe a GLP-1 medication is appropriate for a patient to address weight loss/management, please do not submit a request to Prime Therapeutics to review. Be sure to let the patient know the GLP-1 drugs will not be covered, and it will have to be paid for out of pocket."
Practical implications
No PA submission for weight loss: Florida Blue explicitly asks providers not to submit PA requests for GLP-1 weight-loss medications, as they will be automatically denied
No off-label coverage: Even if a provider believes a GLP-1 is medically necessary for weight management, the benefit exclusion applies regardless of BMI, comorbidities, or clinical justification
No formulary exception: The exclusion is embedded in the plan benefit design, not in the formulary, so formulary exception requests are not applicable
Employer plan variation: Self-funded employer plans may have different coverage rules; verify with the plan administrator
Why Florida Blue excludes weight-loss GLP-1s
Florida Blue has communicated that the exclusion is driven by cost considerations. GLP-1 weight-loss medications are expensive (Wegovy retail approximately $1,350/month), require long-term use to maintain effectiveness, and covering them would increase premiums for all members. This aligns with broader industry trends — KFF research found that ACA marketplace plans rarely cover GLP-1 drugs for obesity.
Medicare Part D GLP-1 coverage
Florida Blue Medicare Advantage and stand-alone Part D plans follow CMS rules for GLP-1 coverage:
T2D coverage
GLP-1 medications for T2D are covered with PA on Florida Blue Medicare Part D plans
Same preferred drug list (Ozempic, Mounjaro, Rybelsus, Trulicity) with PA requirements
Victoza is covered under Medicare plans (not commercial)
Wegovy for cardiovascular risk reduction
CMS has clarified that Wegovy is coverable under Medicare Part D for cardiovascular risk reduction in adults with established cardiovascular disease and obesity/overweight
This is a separate indication from weight loss and follows FDA labeling
Florida Blue Medicare covers Wegovy for this indication with PA
Requires documented cardiovascular disease and BMI ≥ 27 kg/m²
Wegovy for MASH
The FDA approved Wegovy for noncirrhotic MASH with F2–F3 fibrosis
Florida Blue Medicare Part D covers Wegovy for MASH with PA
Requires hepatologist/gastroenterologist consultation and fibrosis confirmation
Zepbound for OSA
The FDA approved Zepbound for obstructive sleep apnea in adults with obesity
Florida Blue Medicare may cover Zepbound for OSA with PA
Weight-loss coverage for Zepbound remains excluded per CMS rules
Prime Therapeutics PA process
Florida Blue contracts with Prime Therapeutics for pharmacy benefit management, including GLP-1 prior authorization:
PA submission
PA requests are submitted through CoverMyMeds or via Prime Therapeutics directly at myPrime.com
Providers can find GLP-1 PA criteria questions on myPrime.com before submitting
For Medicare plans, PA is submitted through the same process
Key considerations for PA submission
Only submit for T2D indications: Do not submit PA requests for weight-loss GLP-1 medications — they will be denied and waste administrative time
Include complete diabetes documentation: A1C results, FPG levels, and provider attestation
Document metformin trial: Include records of metformin use, duration, and reason for switching (inefficacy or intolerance)
Check formulary first: Verify the specific GLP-1 medication's tier and PA requirements on the patient's formulary before prescribing
Common denial reasons and strategies
Top denial reasons
Weight-loss indication: Any GLP-1 request for weight management is automatically denied — this is the most common and least appealable denial
Missing T2D documentation: Failure to provide A1C, FPG, or provider attestation of diabetes diagnosis
No metformin trial: Patient has not tried and failed metformin, metformin combinations, or insulin
Off-label request: GLP-1 prescribed for an indication not approved by FDA or not covered under the plan
Missing clinical records: Incomplete documentation submitted with the PA request
Strategies for prescribers
For T2D patients: Ensure complete documentation before PA submission — A1C, metformin trial, provider attestation
For weight-loss patients: Inform patients that Florida Blue commercial plans do not cover GLP-1s for weight loss; discuss:
Manufacturer savings programs (Novo Nordisk Wegovy savings card, Eli Lilly Zepbound savings card)
HSA/FSA eligible expenses for out-of-pocket costs
Florida Blue wellness programs at Florida Blue Centers (nutrition, weight management, exercise — covered at no extra cost)
For Medicare patients with CVD or MASH: Submit Wegovy PA with documented cardiovascular disease or MASH diagnosis; this has a viable coverage path
For employer self-funded plans: Contact the plan administrator directly — self-funded plans may have different GLP-1 coverage rules than Florida Blue's standard formulary
Prescribing checklist
Before submitting a GLP-1 prior authorization to Florida Blue:
Confirm the patient's plan type (commercial vs. Medicare) and formulary
Determine the clinical indication (T2D, CVD risk reduction, MASH, OSA, or weight loss)
If T2D: document diagnosis with A1C and/or FPG results
If T2D: document metformin trial (duration, dose, outcome)
Do NOT submit PA for weight-loss GLP-1 on commercial plans — it will be denied
If Medicare: check Part D formulary for Wegovy CVD/MASH or Zepbound OSA coverage
Submit through CoverMyMeds or Prime Therapeutics at myPrime.com
Inform patient of expected coverage and out-of-pocket costs
What to monitor
Florida Blue formulary updates: Quarterly formulary reviews may change tier placement for GLP-1 T2D medications
State legislation: Florida has not enacted a GLP-1 coverage mandate, but legislative proposals could emerge
CMS Medicare GLP-1 Bridge: Expected to expand Medicare coverage for GLP-1 weight-loss drugs starting mid-2026; could shift Florida Blue Medicare policy
New Wegovy formulations: Oral Wegovy tablets and higher-dose injectable (7.2 mg) may affect formulary placement
Employer plan changes: Annual enrollment periods may bring changes to employer-sponsored GLP-1 coverage
Sources
Florida Blue, GLP-1 Prior Authorization Requirement for Commercial Plans, January 2025: https://files.guidewell.com/m/7bf6733fcce9a9ab/original/providers-news-2025-pharmacy-glp-commercial-prior-auth-requirement-01-2025.pdf
Florida Blue, GLP-1 Drug Class Overview Bulletin: https://files.guidewell.com/m/3179dbafc2d11f32/original/providers-news-2024-pharmacy-glp-drug-class-04-01-24.pdf
Florida Blue, April 2026 Open Medication Guide: http://www.bcbsfl.com/DocumentLibrary/Providers/Content/MedGuide.pdf
Florida Blue, April 2026 NetResults Medication Guide: https://www.bcbsfl.com/DocumentLibrary/Providers/Content/NetResults_A_MedGuide.pdf
Florida Blue, Provider Prior Authorization: https://www.floridablue.com/providers/medical-pharmacy-info/prior-authorization
Prime Therapeutics, GLP-1 Pipeline Update, February 2026: https://www.primetherapeutics.com/glp-1-pipeline-update-february-2026
CMS, Medicare Part D Drug Coverage: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn
FDA, Wegovy (semaglutide) prescribing information and FDA-approved indications: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011s012s013s014lbl.pdf
KFF, Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans, June 2024: https://www.kff.org/affordable-care-act/costly-glp-1-drugs-are-rarely-covered-for-weight-loss-by-marketplace-plans
